US Patent

US10322139 — Neuroactive steroid formulations and methods of treating CNS disorders

Formulation · Assigned to Sage Therapeutics Inc · Expires 2033-01-23 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of neuroactive steroids, such as allopregnanolone, and methods of using them to treat central nervous system disorders.

USPTO Abstract

Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US10322139
Jurisdiction
US
Classification
Formulation
Expires
2033-01-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.